The stock of Seelos Therapeutics (NASDAQ: SEEL), a clinical-stage biotech that focuses on central nervous system (CNS) afflictions, was hit with an over 24% sell-off on Monday. Seemingly positive clinical trial news was heavily tempered by an analyst downgrade. An open-label study of Seelos' SLS-002 drug aimed at treating acute suicidal ideation and behavior in patients suffering from major depressive disorder produced very promising results.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting